(Corrects first paragraph to say the sale was to a unit of Cooper Cos)
Sept 11 (Reuters) - Teva Pharmaceutical Industries , said it has agreed to sell Paragard, its intrauterine copper contraceptive brand, to a unit of Cooper Cos in a $1.1 billion cash deal.
The sale of the business is the first step in the planned divestment of non-core assets, Teva said on Monday.
The deal includes the drug maker’s manufacturing facility in Buffalo, NY, which produces Paragard exclusively.
The deal comes on a day when Teva named smaller peer Lundbeck’s Kare Schultz as its new chief executive and amid plans for more divestitures. (Reporting by Shailesh Kuber; Editing by Arun Koyyur)